Working… Menu

A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03937453
Recruitment Status : Recruiting
First Posted : May 3, 2019
Last Update Posted : October 8, 2020
Yale University
Information provided by (Responsible Party):
Richard Frank, Nuvance Health

Brief Summary:
The main goal of this study is to explore the relationship between new-onset diabetes mellitus and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pancreatic cancer.

Condition or disease Intervention/treatment
Pancreatic Cancer Pancreatic Neoplasms Diagnostic Test: MRI/MRCP

Detailed Description:
Individuals between 50-80 years of age who have developed diabetes mellitus within the preceding year will be recruited through the offices of primary care physicians and endocrinologists. Those meeting initial criteria will meet with a research nurse and will undergo a secondary screen to determine eligibility. Individuals enrolled in the study will undergo a five-minute psychological survey and donation of a blood sample for bio-bank analysis every 6 months for 3 years. MRI will be performed annually for 2 years (3 in total). Any abnormalities on MRI will be reviewed by a multi-disciplinary tumor board and discussed with the participant.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 800 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus
Actual Study Start Date : January 19, 2018
Estimated Primary Completion Date : January 19, 2028
Estimated Study Completion Date : January 19, 2028

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
New-Onset Diabetes Mellitus
Diabetes Mellitus diagnosed within the past 12 months
Diagnostic Test: MRI/MRCP
An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually

Primary Outcome Measures :
  1. Early Stage Pancreatic Cancer or Precursor Lesions [ Time Frame: Through study completion, up to 3 years ]
    Determine incidence of pancreatic cancer or precursor lesions within a population of new-onset diabetes mellitus individuals

Secondary Outcome Measures :
  1. Relative Risk of Pancreatic Cancer Among Individuals with New-Onset Diabetes [ Time Frame: Through study completion, up to 3 years ]
    Assess utility of MRI as a screening tool for pancreatic cancer and ascertain relative risk of pancreatic cancer in study population of individuals with new-onset diabetes compared to a normal population of the same age

Biospecimen Retention:   Samples With DNA
Serum sample

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
50-80 years of age. New-onset diabetes mellitus (diagnosed with within the preceding 12 months)

Inclusion Criteria:

  • Age between 50-80 years.
  • DM of Confirmed Duration: DM diagnosed within the past 12 months AND documentation of prior normal FPG, OGTT or HbA1c levels within the past 2 years. Requirement for HbA1c ≥ 6.5% OR
  • DM of Unconfirmed Duration: DM diagnosed within the past 12 months BUT no prior record of normal FPG, HbA1c or OGTT within the past 2 years. Requirement for HbA1c ≥ 7.0% OR
  • Transition from pre-Diabetes to Diabetes Mellitus within the past 12 months characterized by a change in the HbA1c of ≥ 0.5% OR
  • DM With Only One FDR: DM diagnosed within the past 12 months that is of Confirmed or Unconfirmed Duration, in an individual with 1 FDR. Requirement for HbA1c ≥ 6.5%.
  • ECOG Performance Status of 0-1.
  • No known contraindications to MRI examination or gadolinium contrast.
  • Willing to undergo MRI and screening for metal implants or metal injury.
  • Recent BUN and Cr
  • Estimated GFR (eGFR) must be greater than 40 mL/min.
  • Ability to provide informed consent.
  • Willing to return to study site for all study assessments.

Exclusion Criteria:

  • Prior history of pancreatic cancer.
  • Presence of metastatic cancer or cancer requiring adjuvant chemotherapy within the past 5 years.
  • Received chemotherapy within the past 6 months. (Hormonal therapy is allowable if the disease free interval is at least 5 years).
  • Hereditary pancreatitis.
  • eGFR < 40 mL/min.
  • Contraindication to MRI examination or gadolinium contrast.
  • Pregnant or nursing women.
  • Co-morbid illnesses or other concurrent disease which, in the judgment of the clinicians obtaining informed consent, would make the participant inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03937453

Layout table for location contacts
Contact: Tammy Lo, APRN 203-822-3551
Contact: Pramila Krumholtz, RN 203-739-7997

Layout table for location information
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06511
Contact: James Farrell, MD   
Principal Investigator: James Farrell, MD         
Western Connecticut Health Network Recruiting
Norwalk, Connecticut, United States, 06856
Contact: Tammy Lo, APRN    203-822-3551   
Principal Investigator: Richard Frank, MD         
Sponsors and Collaborators
Nuvance Health
Yale University
Layout table for investigator information
Principal Investigator: Richard Frank, MD Nuvance Health
Additional Information:
Layout table for additonal information
Responsible Party: Richard Frank, Director of Cancer Research, Nuvance Health Identifier: NCT03937453    
Other Study ID Numbers: 18-01
First Posted: May 3, 2019    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant data for all primary and secondary outcome measures will be made available
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data will be available within 6 months of study completion
Access Criteria: Data access requests will be reviewed on an individual basis post submission. Requestors may be required to sign a data access agreement

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Richard Frank, Nuvance Health:
Diabetes Mellitus
Early Detection
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases